Symbiotec Pharmalab Ltd
- Market Cap ₹ 7,955 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 54.6
- Book Value ₹
- Dividend Yield %
- ROCE 21.1 %
- ROE 17.4 %
- Face Value ₹ 2.00
Pros
- Company's working capital requirements have reduced from 89.3 days to 53.2 days
Cons
- Company has a low return on equity of 13.0% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 623 | 634 | 564 | 674 | 757 | |
| 420 | 529 | 483 | 531 | 538 | |
| Operating Profit | 202 | 105 | 80 | 143 | 219 |
| OPM % | 32% | 17% | 14% | 21% | 29% |
| 9 | 6 | -52 | 20 | 32 | |
| Interest | 7 | 3 | 8 | 8 | 17 |
| Depreciation | 22 | 25 | 28 | 37 | 38 |
| Profit before tax | 183 | 83 | -8 | 118 | 196 |
| Tax % | 26% | 25% | 191% | 25% | 26% |
| 136 | 62 | -23 | 89 | 146 | |
| EPS in Rs | 123.95 | 56.44 | -20.72 | 81.33 | 229.01 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 64% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 13% |
| Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 |
| Reserves | 622 | 684 | 662 | 750 | 900 |
| 47 | 64 | 107 | 52 | 293 | |
| 161 | 136 | 135 | 274 | 145 | |
| Total Liabilities | 842 | 894 | 915 | 1,087 | 1,348 |
| 248 | 266 | 266 | 324 | 317 | |
| CWIP | 27 | 23 | 74 | 19 | 59 |
| Investments | 123 | 130 | 66 | 42 | 44 |
| 445 | 476 | 510 | 702 | 928 | |
| Total Assets | 842 | 894 | 915 | 1,087 | 1,348 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 158 | 24 | 93 | 147 | 83 | |
| -79 | -34 | -132 | -81 | -292 | |
| -79 | 15 | 37 | -63 | 225 | |
| Net Cash Flow | -0 | 4 | -3 | 4 | 16 |
| Free Cash Flow | 116 | -18 | 22 | 107 | 8 |
| CFO/OP | 99% | 45% | 136% | 128% | 54% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 70 | 83 | 73 | 68 | 85 |
| Inventory Days | 309 | 250 | 304 | 378 | 309 |
| Days Payable | 151 | 86 | 109 | 254 | 101 |
| Cash Conversion Cycle | 228 | 246 | 268 | 191 | 293 |
| Working Capital Days | 111 | 137 | 110 | 105 | 53 |
| ROCE % | 12% | 8% | 16% | 21% |
Documents
Annual reports
No data available.